Nanoparticle Based Magnetic Microfluidic concentrator (MMC)

基于纳米颗粒的磁微流控浓缩器 (MMC)

• 批准号: 7348254
• 负责人: Yongqiang Andrew Wang
• 金额: $ 10万
• 依托单位: OCEAN NANOTECH, LLC
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-10 至 2009-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7348254
• 关键词: Affinity; Antibodies; Binding; Biocompatible; Biological Models; Body Fluids; Cancer Detection; Cells; Centrifugation; Charge; Chemistry; Complex; DNA; Devices; Dimensions; Epigenetic Process; Evaluation; Excision; Figs - dietary; G-substrate; Gene Proteins; Genomics; Goals; Lead; Ligands; Magnetism; Malignant Neoplasms; Methods; Microfluidics; Normal Cell; Numbers; Peptides; Performance; Phase; Physical condensation; Preparation; Proteins; Proteomics; Protocols documentation; Rate; Recovery; Recycling; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Solutions; Stream; Surface; System; United States National Institutes of Health; Water; Work; base; cancer cell; epigenomics; improved; instrumentation; iron oxide; magnetic field; nanoparticle; size; success

DESCRIPTION (provided by applicant): Enriched abnormal exfoliated cells and biomolecules will enable genomic, proteomic, and epigenomic analyses to detect cancer-specific alterations in expressed genes, protein/peptide profiles, and epigenetic markers. The ability to carry out such enrichment and analyses in a routine way using body fluids may lead to improvements in cancer detection. This NIH SBIR Phase I proposal is to develop a high throughput and high enrichment factor system for the enrichment of rare cancer cells and cell fragments. In phase I, the enrichment of cancer cell, cancer protein and all DNAs will be studied through our model system. In phase II, the cancer cells and cell fragment in body fluids will be used to optimize this system. The final deliverables will include a MMC, antibody immobilized MNPs and all necessary protocols.

描述(由申请人提供)：丰富的异常脱落细胞和生物分子将使基因组、蛋白质组和表观基因组分析能够检测表达基因、蛋白质/肽谱和表观遗传标记中的癌症特异性变化。使用体液以常规方式进行这种浓缩和分析的能力可能会改善癌症检测。 这项NIH SBIR第一阶段的建议是开发一个高通量和高浓缩因子系统，用于浓缩稀有癌细胞和细胞碎片。在第一阶段，我们将通过我们的模型系统来研究癌细胞、癌细胞蛋白和所有DNA的浓缩。在第二阶段，将利用癌细胞和体液中的细胞碎片来优化这一系统。最终的交付成果将包括MMC、抗体固定化MNPs和所有必要的方案。